Form 4: Intuitive Surgical CFO Jamie Samath Executes Stock Transactions Under 10b5-1 Plan

Intuitive Surgical's CFO, Jamie Samath, engaged in multiple stock option exercises and sales on November 8th and 11th, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Jamie Samath, CFO of Intuitive Surgical, executed multiple transactions involving the company's stock on November 8th and 11th, 2024.
• These transactions included the exercise of non-qualified stock options and the sale of common stock.
• The transactions were conducted under a pre-arranged trading plan that complies with SEC Rule 10b5-1.
• On November 8th, Samath acquired a total of 22,903 shares through option exercises at various prices and sold 22,903 shares at $525.
• On November 11th, Samath acquired 269 shares through option exercises at various prices and sold 269 shares at $539.89.
• The trading plan expires on May 6, 2025.

Sentiment

Score: 6

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, which is neither particularly positive nor negative. The sentiment is neutral to slightly positive due to the transparency of the 10b5-1 plan.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to avoid accusations of insider trading.
• The plan provides transparency and predictability to the market regarding the executive's trading activity.

Risks

• The sale of a significant number of shares by a high-ranking executive could potentially be interpreted negatively by the market, although this is mitigated by the pre-arranged trading plan.
• The market may react to the volume of shares sold, even if the transactions are part of a pre-planned strategy.

Future Outlook

The trading plan will continue until May 6, 2025, and further transactions may occur under this plan.

Industry Context

This is a routine filing related to executive stock transactions and is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to manage insider trading risks.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the medical device industry such as Medtronic and Stryker.
• The volume of shares traded is not unusual for an executive at this level, and the prices are within the typical range for stock option exercises and sales.
• The vesting schedules for the options are also typical, with a mix of time-based and performance-based vesting.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, but the pre-arranged nature of the trades should mitigate any negative perception.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Next Steps

• Further transactions may occur under the 10b5-1 trading plan until its expiration on May 6, 2025.

Key Dates

Keywords

stock options, insider trading, SEC Form 4, 10b5-1 plan, Intuitive Surgical, Jamie Samath, stock sale, executive compensation